Company Overview and News
REVA Medical Inc (ASX:RVA) has conducted the first implant of its bioresorbable (naturally dissolving) scaffold “Fantom” at Kantonsspital Baselland in Liestal, Switzerland.
SAN DIEGO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) announced today that its Board of Directors has appointed Ray Larkin Jr., a current member of the Company’s Board of Directors, as Chairman of the Board, effective September 18, 2017. Mr. Larkin replaced Brian Dovey, who stepped down as Chairman, but will remain on the Company’s Board of Directors. (15-0)
Bioabsorbable stents function like normal medical stents. The main difference between regular stents and bioabsorbable stents is the material which is used in their manufacturing; bioabsorbable stents use material which is easily absorbed in the body. (1-0)
SAN DIEGO, July 13, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA), as part of its transition to commercial operations, today announced the hiring of a new chief financial officer, a vice president of European sales, and the appointment of a new director to its board. These changes signal the shift in focus to commercial roll out of Fantom, which has commenced in Europe. As part of these changes, the Company also announced the retirement of two long-serving executives and one board member.
SAN DIEGO, June 19, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) announces that it has closed the second tranche and, therefore, has completed the financing transaction announced in April 2017 and approved by the Company’s shareholders on June 1, 2017. Completion occurred on June 16, 2017 with the receipt of US$13.3 million cash proceeds in exchange for the issuance of US$13.
SAN DIEGO, May 17, 2017 (GLOBE NEWSWIRE) -- Today at the Paris Course on Revascularization (“EuroPCR”), REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) sponsored a symposium entitled, Fantom: performance gains and clinical data for a next generation BRS, which highlighted the recently announced clinical data from the FANTOM II trial. Information regarding the Company’s newly initiated clinical trials and plans for expansion was also presented.
SAN DIEGO, May 16, 2017 (GLOBE NEWSWIRE) -- At the Paris Course on Revascularization (“EuroPCR”) being held this week in Paris, France, REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) announced sustained positive clinical results from the FANTOM II clinical trial. The trial is evaluating the safety and performance of the Company’s Fantom sirolimus-eluting bioresorbable coronary scaffold in 240 patients outside the United States.
Good afternoon and welcome to AtriCure's First Quarter 2017 Earnings Conference Call. My name is Shannon, and I'll be your coordinator for the call today. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes.
SAN DIEGO, April 24, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that it has entered into an agreement with several institutional and one corporate investor to provide funding for the Company’s ongoing operating and capital needs. Under the agreement, the Company will issue convertible notes, along with options for the purchase of REVA’s common stock.
Welcome to your weekly roundup of EP Vantage’s snippets – short takes on smaller news items.
SAN DIEGO, April 03, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce it has received CE Mark approval for its Fantom drug-eluting bioresorbable coronary scaffold, which offers multiple and substantial performance advantages over first-generation scaffolds on the market today. Fantom is REVA’s first commercial product.
The bioabsorbable stents market has evolved with the advances in technology and innovative products in the medical field. Stents are being increasingly used to treat medical conditions. The vendors are focusing on developing products that are safe, easy to use, widely available, and cost-effective. Also, some companies are adopting creative strategies and developing innovative products to ensure product differentiation in the market.
Interventional cardiology devices are primarily related to heart disease, and most of the heart diseases have some serious medical conditions, such as angina, congestive heart failure, and arrhythmias. These are often caused by partially blocked coronary arteries, which is the most common cause of death globally. Since the 1980s, balloon angioplasty has been the standard method for treating coronary artery disease.
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton